Wolverine Trading
GNMX

Wolverine Trading’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Wolverine Trading’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,233
Closed -$15.3K – 5799
2017
Q3 		$14K Sell
11,233
-11,803
-51% -$15.1K ﹤0.01% 4317
2017
Q2 		$31K Buy
+23,036
New +$33.3K ﹤0.01% 4121

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wolverine Trading's GNMX Position: Q4 2017 in Review

Wolverine Trading sold out of Aevi Genomic Medicine Inc (GNMX) in Q4 2017, closing a stake of 11,233 shares — an estimated $15.3K sold.

Wolverine Trading first reported a position in GNMX in Q2 2017 and held it in 2 quarters. The position peaked at $31K in Q2 2017. 45 funds tracked by Wall St. Rank hold GNMX as of Q4 2017.

  • Wolverine Trading reported no remaining Aevi Genomic Medicine Inc position as of Q4 2017 after selling out during the quarter.
  • Wolverine Trading sold 11,233 Aevi Genomic Medicine Inc shares in Q4 2017, an estimated $15.3K.
  • Wolverine Trading first reported a position in Aevi Genomic Medicine Inc in Q2 2017 and held it in 2 quarters.
  • Wolverine Trading's Aevi Genomic Medicine Inc position peaked at $31K in Q2 2017.
  • 45 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q4 2017.

Based on Wolverine Trading's 13F filing for Q4 2017, filed 14 Feb 2018.